Indivior's Suboxone decline slower than feared as company bets on new opioid drug

(Reuters) - Indivior Plc's best selling drug is losing market share slower than some analysts had predicted and its new drug is performing on target, lifting shares in the company despite its forecast of a possible loss this year.The U.S. Supreme Court earlier this year cleared the way for market access to cheaper alternatives to Indivior's blockbuster opioid addiction treatment Suboxone film, a move which the company itself said could result in the rapid loss of market share.The British based..